Heron Therapeutics receives expanded indications from the FDA for Zynrelef
Click Here to Manage Email Alerts
Key takeaways:
- Heron Therapeutics announced expanded indications for Zynrelef to include soft tissue procedures.
- Zynrelef is a local anesthetic that includes a combination of bupivacaine and meloxicam.
Heron Therapeutics Inc. announced Zynrelef has received expanded indications from the FDA for use in soft tissue and additional orthopedic surgical procedures, according to a press release.
Zynrelef, a postoperative pain management drug, is an extended-release dual-acting local anesthetic that delivers a fixed-dose combination of bupivacaine and low-dose meloxicam, according to the release.
Zynrelef previously received FDA approval for lower extremity total joint arthroplasty procedures in adults. It is now FDA approved for foot and ankle procedures and several procedures in which direct exposure to articular cartilage is avoided, according to the release.
“The expanded indication is poised to have a transformative impact on patient care, providing health care professionals with a versatile and effective solution for managing postoperative pain across an even wider range of surgical procedures,” Craig Collard, CEO of Heron Therapeutics, said in the release. “The new label expansion and recent partnership with CrossLink, combined with the potential approval of the Vial Access Needle later this year, are expected to have a significant positive impact for Zynrelef and the company,” Collard added.
Read more about
Click Here to Manage Email Alerts